# US 2022/0089612 A1 · Heterocyclic compounds as prmt5 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0089612 A1
- Document ID: US20220089612A1
- Status: Published application
- Kind: A1
- Application number: 17/532,964
- Filed: 2021-11-22
- Published: 2022-03-24
- Earliest claimed: 2017-12-05
- Assignees: Angex Pharmaceutical, Inc.
- Applicants: Angex Pharmaceutical, Inc.
- Inventors: Wen-Lian Wu; Zhiqiang Yang; Francis Lee; John Qiang Tan
- Web page: https://patentgrep.com/patent/US20220089612A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D 487/04: Ortho-condensed systems
- C07H 19/14: Pyrrolo-pyrimidine radicals
- C07H 19/23: Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

The present disclosure describes novel heterocyclic PRMT5 inhibitors and methods for preparing them. The pharmaceutical compositions comprising such PRMT5 inhibitors and methods of using them for treating cancer, infectious diseases, and other PRMT5 associated disorders are also described.

## Claims

### Claim 1

A compound represented by a formula:
or a pharmaceutically acceptable salt thereof;
wherein
(Ring A) is an optionally substituted 4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl;
(Ring B) is an optionally substituted fused tricyclic heterocyclic ring system containing 1, 2, 3, 4, or 5 ring N atoms, 0 or 1 ring O atom, and a fused benzene ring, wherein the fused benzene ring is directly attached to L;
X is —O— or —CH2—;
L is optionally substituted C1-3 hydrocarbylene, optionally substituted —O—C1-2 hydrocarbylene-, optionally substituted —S—C1-2 hydrocarbylene-, or optionally substituted —NRA—C1-2 hydrocarbylene-; and
RA is H, C1-6 hydrocarbyl, C1-6 heteroaryl, C1-6 heterocycloalkyl, —C(O)—C1-6 alkyl, —C(O)NH—C1-6 alkyl, or —C(O)OC1-6 alkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Ring A comprises:
and Ring B comprises:
wherein each structure is optionally substituted;
G is N or CR;
Y is —N(RA)—, N, C(RC), or —C(RCRD)—, or —C(RCRD)—C(RCRD)—;
Z is a bond, —N(RA)—, N, C(RC), or —C(RCRD)—;
W is a bond, —N(RA)—, N, —O—, C(RC), or —C(RCRD)—;
dashed line represents optionally with or without a bond;
each R is independently H, F, Cl, Br, I, —NRARB, C1-6 hydrocarbyl, —OH, —CN, or —O—C1-6 alkyl;
each RC, and each RD are independently H, F, Cl, Br, I, —NRARB, C1-6 hydrocarbyl, —OH, —CN, ═O, or —O—C1-6 alkyl;
each RA and each RB are independently H, C1-6 hydrocarbyl, C1-6 heteroaryl, C1-6 heterocycloalkyl, —C(O)—C1-6 alkyl, —C(O)NH—C1-6 alkyl, or —C(O)OC1-6 alkyl; and
wherein each R, each RA, each RB, each RC, and each RD are independently optionally halogenated.

### Claim 3 (depends on 1)

The compound of claim 1, wherein Ring A comprises unsubstituted 4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein Ring B is an optionally substituted fused tricyclic heteroaromatic ring system.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Ring B contains one ring N atom, two ring N atoms, three ring N atoms, or four ring N atoms.

### Claim 6 (depends on 1)

The compound of claim 1, wherein Ring B contains one ring O atom.

### Claim 7 (depends on 1)

The compound of claim 1, wherein Ring B is optionally substituted 2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted 3,3-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted 1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted 1H-pyrazolo[3,4-b]quinolin-7-yl, optionally substituted 5-amino-2,3-dihydroimidazo[1,2-c]quinazolin-8-yl, optionally substituted 5-aminoimidazo[1,2-c]quinazolin-8-yl, optionally substituted (1aS,7bR)-2-amino-1a,7b-dihydro-1H-cyclopropa[c]quinolin-5-yl, optionally substituted (1aR,7bS)-2-amino-1a,7b-dihydro-1H-cyclopropa[c]quinolin-5-yl, optionally substituted 3,4-dihydro-1H-[1,2]oxazino[3,4-b]quinolin-8-yl, optionally substituted 1,3-dihydroisoxazolo[3,4-b]quinolin-7-yl, optionally substituted (R)-3-methyl-3,4-dihydro-1H-[1,2]oxazino[3,4-b]quinolin-8-yl, optionally substituted 3H-imidazo[4,5-b]quinolin-6-yl, optionally substituted (S)-2-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted (R)-2-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted (S)-2-cyclopropyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted (R)-2-cyclopropyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted (R)-2-ethyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted (S)-2-isopropyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted (S)-2-(tert-butyl)-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted (R)-2-allyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted 2,2-dimethyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl, optionally substituted 1′,3′-dihydrospiro[cyclopropane-1,2′-pyrrolo[2,3-b]quinolin]-7′-yl, optionally substituted 1,2,3,4-tetrahydrobenzo[b][1,8]naphthyridin-8-yl, optionally substituted (S)-2-methyl-1,2,3,4-tetrahydrobenzo[b][1,8]naphthyridin-8-yl, optionally substituted (R)-2-methyl-1,2,3,4-tetrahydrobenzo[b][1,8]naphthyridin-8-yl, optionally substituted (S)-2-cyclopropyl-1,2,3,4-tetrahydrobenzo[b][1,8]naphthyridin-8-yl, optionally substituted 2,3,4,5-tetrahydro-1H-azepino[2,3-b]quinolin-9-yl, optionally substituted (S)-(2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-2-yl)methanol, or optionally substituted 1,2,3,4-tetrahydrobenzo[b][1,8]naphthyridin-3-ol.

### Claim 8 (depends on 1)

The compound of claim 1, wherein X is —CH2—.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X is —O—.

### Claim 10 (depends on 1)

The compound of claim 1, wherein L is —CH2—CH2—.

### Claim 11 (depends on 1)

The compound of claim 1, wherein L is —CH2—CH2—CH2—

### Claim 12 (depends on 1)

The compound of claim 1, wherein L is —CH2O—.

### Claim 13 (depends on 1)

The compound of claim 1, wherein L is —O—CH2—.

### Claim 14

A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is optionally substituted (1S,2R,3S,5R)-3-(2-(2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-(2,3-dihydroimidazo[1,2-c]quinazolin-8-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-(imidazo[1,2-c]quinazolin-8-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-((1aS,7bR)-1a,7b-dihydro-1H-cyclopropa[c]quinolin-5-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-((1aR,7bS)-1a,7b-dihydro-1H-cyclopropa[c]quinolin-5-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-(1H-pyrazolo[3,4-b]quinolin-7-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (2R,3S,4R,5R)-2-(2-(2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-7-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol, optionally substituted (2R,3S,4R,5R)-2-(2-(2,3-dihydroimidazo[1,2-c]quinazolin-8-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol, optionally substituted (2R,3S,4R,5R)-2-(2-(imidazo[1,2-c]quinazolin-8-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol, optionally substituted (1S,2R,3S,5R)-3-(2-(1H-pyrrolo[2,3-b]quinolin-7-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, (1S,2R,3S,5R)-3-(2-(3,4-dihydro-1H-[1,2]oxazino[3,4-b]quinolin-8-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, (1S,2R,3S,5R)-3-(2-(1,3-dihydroisoxazolo[3,4-b]quinolin-7-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1R,2S,3R,5S)-3-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(2-(1,3,4,5-tetrahydro-[1,2]oxazepino[3,4-b]quinolin-9-yl)ethyl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-(3H-imidazo[4,5-b]quinolin-6-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-(3H-[1,2,3]triazolo[4,5-b]quinolin-6-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1S,2R,3S,5R)-3-(2-(2,3-dihydro-1H-pyrazolo[3,4-b]quinolin-7-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol, optionally substituted (1R,2S,3R,5S)-3-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(2-(1,2,3,4-tetrahydrobenzo[b][1,8]naphthyridin-8-yl)ethyl)cyclopentane-1,2-diol, optionally substituted (1R,2S,3R,5S)-3-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(2-(2,3,4,5-tetrahydro-1H-azepino[2,3-b]quinolin-9-yl)ethyl)cyclopentane-1,2-diol, optionally substituted (2R,3S,4R,5R)-2-(2-(1H-pyrazolo[3,4-b]quinolin-7-yl)ethyl)-5-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)tetrahydrofuran-3,4-diol, optionally substituted (2R,3R,4S,5R)-2-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(2-(1,2,3,4-tetrahydrobenzo[b][1,8]naphthyridin-8-yl)ethyl)tetrahydrofuran-3,4-diol, or optionally substituted (1R,2S,3R,5S)-3-(7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-(2-(1,2,3,4-tetrahydropyridazino[3,4-b]quinolin-8-yl)ethyl)cyclopentane-1,2-diol.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound is deuterated.

### Claim 16 (depends on 1)

The compound of claim 1, wherein each substituent, if present, of Ring A, Ring B, and L, has a molecular weight of 15 g/mol to 200 g/mol.

### Claim 17

A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:

### Claim 18 (depends on 1)

A method of treating cancer, infectious disease, and other PRMT5-related disease or disorder comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in combination with at least one pharmaceutically acceptable carrier.
